CompletedPhase 1NCT06206811

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

Studying Blau syndrome

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Odyssey Therapeutics
Principal Investigator: Anthony Opipari, MD, PhD
Odyssey Therapeutics
Intervention: OD-07656(drug)
Enrollment: 101 enrolled
Eligibility: 18-64 years · All sexes
Timeline: 2024 – 2024

Study locations (1)

Nucleus Network Pty Ltd, Melbourne, Victoria, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06206811 on ClinicalTrials.gov

Other trials for Blau syndrome

Additional recruiting or active studies for the same condition.

ENROLLING BY INVITATIONPHASE4NCT06660329
Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
Peking Union Medical College Hospital
ENROLLING BY INVITATIONNCT06688838
Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome
Tongji Hospital

See all trials for Blau syndrome →

← Back to all trials